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ABSTRACT
Background and Objectives: Vasospastic angina (VA) is a specific type of coronary artery disease and develops as a result 
of coronary artery spasm. Recently, a few studies have revealed that VA caused by coronary artery spasm is related to genetic 
traits. The objective of this study was to use the recently developed technique of array comparative genomic hybridization 
(CGH) to screen the genetic aberrations of VA. Subjects and Methods: To identify candidate genes that might be causally 
involved in the pathogenesis of VA, genomic deoxyribonucleic acids were extracted from whole blood of 28 patients with VA 
who presented at Department of Cardiology at Seoul St. Mary’s Hospital, Seoul, Korea. The copy number profiles of these 
patients was then analyzed using array CGH and reverse transcriptase (RT) quantitative polymerase chain reaction (PCR). 
Results: Array CGH revealed gains in 31 different regions, with losses in the 4q35.2, 7q22.1, 10q26.3, 15q11.2, 16p13.11, 
17p11.2 and 19q13.3 regions (more than 32% aberration in these regions). Several loci were found to be frequently including 
gains of 5p and 11q (50% of samples). The most common losses were found in 7q (54% of samples). Copy number aberrations 
in chromosomal regions were detected and corresponding genes were confirmed by RT quantitative PCR. The fold change 
levels were highest in the CTDP1 (18q23), HDAC10 (22q13.33), KCNQ1 (11p15.5-p15.4), NINJ2 (12p13.33), NOTCH2 
(1p12-p11.2), PCSK6 (15q26.3), SDHA (5p15.33), and MUC17 (7q22.1) genes. Conclusion: Many candidate chromosomal 
regions that might be related to the pathogenesis of VA were detected by array CGH and should be systematically investi-
gated to establish the causative and specific genes for VA. (Korean Circ J 2011;41:385-393)
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Introduction
Vasospastic angina (VA), also called Prinzmetal’s angina or 
variant angina, is a specific type of coronary artery disease and 
is developed due to not atherosclerosis but coronary artery 
spasm. This disease can cause acute coronary syndrome, in-
cluding acute myocardial infarction, ventricular tachycardia, 
fibrillation or electro mechanical dissociation, and even sud-
den cardiac death.
1) The incidence of VA is higher in Asians 
than Caucasians or Blacks,
2)3) which strongly suggests that ge-
netic traits might be involved in the pathogenesis of VA.
4-11) 
Studies have shown that the loss of Kir6.1 {pore-forming 
inwardly rectifying K
+ (Kir) channel subunit} or SUR2 (sulfo-
nylurea receptor regulatory subunit of KATP channel) by re-
lated gene deletions in mice induced VA.
4)5) So far, only these 
two genes have been shown to be associated with gene copy 
number alterations. Other investigations showed gene poly-
morphisms
6-8) and functional expression
9-11) in VA. Related 
gene polymorphisms in VA included an endothelial nitric 
oxide synthase gene,
6) adrenergic receptor gene,
7) and the pa-
raoxonase 1 gene.
8) The Rho-associated kinase gene
9) and se-
rotonin receptor (5-HT1Dβ) gene
10)11) were also shown to be re-
lated to VA by their functional expression. To date, there have 
been no studies on deoxyribonucleic acid (DNA) copy num-
ber alterations in the whole human genome among patients 386   DNA Copy Number Aberrations in Vasospastic Angina 
with VA. The recent development of array-comparative ge-
nomic hybridization (CGH) provides a means to quantita-
tively measure DNA copy number aberrations and to map 
them directly to genomic sequences.
12-14) Also, tiling resolu-
tion DNA microarrays comprised of large-insert genomic 
clones such as bacterial artificial chromosomes (BACs) are a 
very useful and accurate method for detecting genomic ab-
errations in many genetic diseases.
15)16) Furthermore, array-
CGH with BAC clones, has been proven to be a very useful 
and accurate tool for detecting genomic aberrations in whole 
blood samples for schizophrenia, epilepsy and mental retar-
dation,
17-19) as well as in tissue from some cancers.
20-24) Both 
fluorescence in situ hybridization (FISH) and real-time poly-
merase chain reaction (RT-PCR) have also been applied em-
pirically to confirm array-CGH results.
17)18)21-24) 
In the study presented here, we analyzed genomic DNA copy 
number aberrations in whole blood from 28 patients with 
VA using array CGH. Genetic aberrations, for a subset of gain-
ed or lost gene, were confirmed by RT-PCR.
Subjects and Methods
Clinical description 
Peripheral blood samples were collected from 28 patients 
with VA at the Department of Cardiology at Seoul St. Mary’s 
Hospital, Seoul, Korea. In this study, the diagnosis of VA was 
made when patients met all of the following criteria: 1) re-
petitive burning or squeezing retrosternal chest pain, 2) def-
inite positive response by coronary angiography with intra 
coronary acetylcholine provocation test, 3) no significant athe-
rosclerotic stenosis in coronary artery (<50% narrowing of 
the coronary luminal diameter) according to quantitative co-
ronary angiography. Blood samples were collected from 8 
women and 20 men, aged 34-71 years (mean age±standard 
deviation, 56.44±11.4 in years). The clinical characteristics 
of the patients are shown in Table 1. Genomic DNA was extr-
acted using a Puregene DNA isolation kit (Qiagen, Hilden, 
Germany). Reference DNA was pooled from 10 gender-mat-
ched (male), normal, healthy control subjects. All patients gave 
written informed consent to participate in this study. The pro-
tocol of this study was approved by the institutional review 
board of Seoul St. Mary’s Hospital, The Catholic University 
of Korea.
Array comparative genomic hybridization
Array CGH analyses were conducted on 28 individual sam-
ples using commercial MACArray
TM Karyo 4K BAC-chips 
(Macrogen, Seoul, Korea) with 4,030 BAC clones, in dupli-
cate, on the whole human genome with a resolution of about 
1 Mbp. Array CGH was performed as described previous-
ly.
25) Briefly, 500-700 ng target and reference DNAs were de-
natured in the presence of random primer and reaction buf-
fer (BioPrime
® DNA Labeling System, Invitrogen, Carlsbad, 
CA, USA) at 98-100°C for 5 minutes, and then cooled on ice 
for 5 minutes. The denatured DNA was differentially labeled 
with 3 μL of 1 mM Cy3- and Cy5-conjugated dCTP by ran-
dom primed labeling (Perkin Elmer, Waltham, MA, USA). 
The mixture was incubated with a Klenow fragment at 37°C 
overnight. After labeling, unincorporated nucleotides were 
removed using MicroSpin
TM G-50 columns (Amersham Bio-
sciences, Buckinghamshire, UK). Cy3- and Cy5-labeled test 
DNA and reference DNA were mixed with 50 μL of human 
Cot-1 DNA for blocking of repeat sequences. After purifica-
tion, this mixture was resolved in hybridization buffer (Mac-
rogen) containing yeast tRNA for blocking of non-specific nu-
cleotides binding. 
After the MACArray
TM-Karyo 4K BAC-chip was prehy-
bridized in hybridization buffer with salmon sperm DNA 
for 1 hour, chips were hybridized with the purification mix-
ture. It was then incubated for 72 hours in the 37°C hybridiz-
ation chamber (BioMicro systems, Salt Lake City, UT, USA). 
After hybridization was complete, array chips were washed in 
50% formamide-2x SSC at 46°C for 15 minutes, and 0.1% 
SDS-2x SSC at 46°C for 30 minutes. Next, the chips were wa-
shed in 50% sodium phosphate-0.1% NP40 for 15 minutes 
followed by washing with 2x SSC for 15 minutes at room 
temperature. After spin drying, hybridized arrays were scann-
ed with a Genepix
TM (Axon Instruments, Sunnyvale, CA, USA). 
Data analysis 
Raw signal intensities from the arrays were measured us-
ing the MAC Viewer v1.6.3 software (Macrogen). Log2 (Cy3 
intensity/Cy5 intensity ratios) were normalized by using the 
median of fluorescence ratios computed from the houseke-
eping DNA control fragments linearly distributed across the 
genome. Measurements flagged as unreliable by MAC Vie-
wer v1.6.3 were removed from subsequent analysis. The th-
reshold corresponds to 2 standard deviation (SD) values from 
the mean. The information on each individual clone was ob-
tained from the UCSC Genome Bioinformatics database 
(May 2004 freeze, http://genome.ucsc.edu).
Reverse transcriptase quantitative polymerase 
chain reaction 
To confirm the level of genomic imbalances identified by 
Table 1. The clinical characteristics of patients with vasospastic 
angina
Characteristic Value
Number of samples 28
Age, mean±standard deviation (years) 56.4±11.4
Male (%) 20 (71.4)
Current smoker (%) 11 (39.3)
Current alcohol drinking (%) 14 (50)Suk Min Seo, et al.   387
array CGH in this study, DNA samples with obvious ge-
nomic changes were analyzed using RT quantitative PCR.
26) 
The reaction was performed in a total volume of 50 μL, incl-
uding 25 μL of 2x IQ
TM SYBR
® green supermix (Bio-Rad, 
Hercules, CA, USA), 10 ng of DNA, and 10 pmol of each pri-
mer.
27) Forty cycles of amplification, data acquisition, and 
data analysis were performed in an iCycler (Bio-Rad). Prim-
ers for eight genes (CTDP1, HDAC10, KCNQ1, NINJ2, 
NOTCH2, PCSK6, SDHA, and MUC17) were selected and 
the position of each clone was obtained from the UCSC ge-
nome database (Table 2). The relative genomic copy number 
was calculated using the comparative CT Method.
28) GAPDH 
was used as an endogenous reference.
28-30)
Results
Genomic deoxyribonucleic acid copy number
changes and pattern of aberrations 
Chromosomal copy number changes were detected by ar-
ray-CGH in VA. Copy number changes were presented as in-
dividual chromosome plots of log2 ratio of normalized Cy3 : 
Cy5 intensities versus chromosome regions for each of the in-
dividual 28 cases of VA. Table 3 shows the frequency of ab-
erration, ranging from 7 (25% of chromosomal gain and loss) 
to 15 (54% of chromosomal loss at 7q) in 28 samples. Over-
all, the individual chromosomal aberration pattern was not 
random and tended to be consistent, showing DNA gains in 
1p, 1q, 2p, 2q, 3p, 3q, 4p, 4q, 5p, 5q, 6p, 6q, 7q, 8p, 8q, 9q, 
10p, 10q, 11p, 11q, 12q, 13q, 14q, 15q, 16p, 16q, 17p, 17q, 
18q, 20p, 20q, 21q, and 22q; and showing DNA losses in 2p, 
4q, 7q, 10q, 15q, 16p, 17p, and 19p. DNA gains, rather than 
DNA losses, were more frequently observed. The most fre-
quent gain detected was at 5p15.33, and 11q12.2 (50%). Fre-
quent DNA gains also were observed in 12p13.33, 14q32.33, 
and 15q11.2 in 13 samples (46%), and in 12p13.33 (43%), 
1p12-p11.2, 4p15.1, 8q22.2, 11q25, and 15q26.3 in 11 samples 
(39%). Frequent gains (36%) were located at: 1q44, 3q24, 
11q23.3, 15q11.2, 15q25.2, 15q26.3, 16p12.1, 16p13.2, 17p12, 
18q12.3, and 21q11.2. Other regions with 25-32% frequency 
of DNA gains included 1p12-p11.2, 1p12, 1p21.1, 2p11.2, 
2q21.2-q21.3, 2q22.1, 2q23.3, 2q31.1, 2q37.3, 3p14.1, 3q12.3, 
4p15.1, 4p15.2, 4q24, 4q32.3, 4q34.3, 4q35.2, 5p12, 5p15.2, 
5p15.33, 5q15, 6p12.2, 6q24.1, 7q11.23, 7q22.2, 8p23.3, 
8q24.3, 9q22.1, 9q22.32, 9q33.3, 10p15.3, 10q11.23, 10q23.1, 
10q26.3, 11p15.5, 11p15.5-p15.4, 11q14.1, 11q23.1, 11q23.2, 
12p13.33, 12q22, 13q33.3, 14q31.3, 15q26.3, 16p11.2, 
16q24.1, 17q24.3, 17q25.3, 18q23, 20p12.2, 20q12, 20q13.33, 
21q11.2, 21q22.3, 22q12.2, and 22q13.33. The most com-
mon genomic losses were observed in 7q22.1 (54%), 4q35.2 
(43%), and 15q11.2 (39%), 10q26.3 (36%). Other regions with 
25-32% frequency of DNA losses included 2p24.1, 7q36.3, 
10q26.3, 16p13.11, 16p13.3, 17p11.2, and 19p13.3 (Table 3). 
Fig. 1 shows chromosomal aberration regions. 1p12-p11.2, 
5p15.33, 11p15.5-p15.4, 12p13.33, 15q26.3, 18q23, and 
22q13.33 contained CTDP1, HDAC10, KCNQ1, NINJ2, 
NOTCH2, PCSK6, and SDHA genes (gained regions), while 
loss region 7q22.1 contained MUC17 gene.
Result according to reverse transcriptase 
quantitative polymerase chain reaction
To confirm the array CGH results, differential fold change 
was evaluated by RT quantitative PCR in VA samples. The re-
sults showed chromosomal fold changes in CTDP1 (18q23), 
HDAC10 (22q13.33), KCNQ1 (11p15.5-p15.4), NINJ2 (12p 
13.33), NOTCH2 (1p12-p11.2), PCSK6 (15q26.3), SDHA 
(5p15.33), and MUC17 (7q22.1). Fig. 2 shows the RT PCR 
results. In gained regions of 7 genes, {CTDP1, HDAC10, 
KCNQ1, NINJ2, NOTCH2, PCSK6, and SDHA (A-G)}, the 
relative fold increases in RT quantitative PCR corresponded 
with array-CGH results. In MUC17 (H), the decrease in fold 
differences noted by RT quantitative PCR was similar to that 
seen with array-CGH. The N-value was delineated in RT PCR. 
The results compared linear-ratios in array-CGH, were de-
monstrated generally larger by RT quantitative PCR analysis 
than those by array-CGH analysis.
Table 2. Primer pairs used for reverse transcriptase quantitative polymerase chain reaction analysis
Genes Primer forward Primer reverse Chromosomal region
Gain
CTDP1 GTAACGGAGGCTGGTGTGAT ACTGCTTTGGAAAAGCCTGA 18q23 
HDAC10 CACTGTTCACCTGTGGGATG GCCTGGCTACAGAACGAGAC 22q13.33 
KCNQ1 TGCTAGAAGGGGCAGTGAGT TCAATTTTGGGGATCTCAGC 11p15.5-p15.4 
NINJ2 CGCCTGTAATCCCACACTTT CTCAAGGTCCGGAGTAGCTG 12p13.33
NOTCH2 GGCAACTACAACAGCCCAAT TCATTTCTGCAGCTGGTCAC 1p12-p11.2 
PCSK6 GGCAACAAAAGAAAGCAAGC TCTCAACAGCTGGGAGAGGT 15q26.3
SDHA CTGAGTGATGCCCTGCAGTA TTCCACGAGCAGAGGAAACT 5p15.33 
Loss
MUC17 GCCAGGCTGTTCTTGAACTC GAAGACGTCCAGACCTGAGC 7q22.1 388   DNA Copy Number Aberrations in Vasospastic Angina 
Table 3. Recurrent gains/losses in spasms {>7 (25%) frequencies}
Chromosomal region Frequency (%) Bac_start (bp) Bac_end (bp) Size (bp) Contained genes
Gain
1p12-p11.2* 11/28 (39) 120390109 120485103 94994 NOTCH2
1p12-p11.2 8/28 (29) 120214296 120390114 175818 ADAM30, NOTCH2
1p12 8/28 (29) 118491301 118584699 93398 SPAG17
1p21.1 8/28 (29) 103961840 103992000 30160 AMY2A
1q44 10/28 (36) 246886515 246967485 80970 OR5BU1
2p11.2 7/28 (25) 86071614 86160853 89239 POLR1A
2q21.2-q21.3 8/28 (29) 134702634 134804417 101783 MGAT5
2q22.1 7/28 (25) 139564813 139702127 137314
2q23.3 8/28 (29) 150646532 150741461 94929
2q31.1 8/28 (29) 177310814 177395162 84348 FUCA1P
2q37.3 7/28 (25) 240550837 240713841 163004 NDUFA10, OR6B2, OR6B3, OR5S1P
3p14.1 8/28 (29) 67409363 67499993 90630
3q12.3 8/28 (29) 103624911 103710584 85673 ZPLD1
3q24 10/28 (36) 149871152 149960984 89832 RPL38P1, AGTR1
4p15.1 11/28 (39) 29961339 30093505 132166
4p15.1 7/28 (25) 28058051 28175610 117559
4p15.2 8/28 (29) 26883925 26969030 85105
4p15.2 8/28 (29) 24962384 25050952 88568 ZCCHC4, ANAPC4
4q24 8/28 (29) 105045356 105165560 120204
4q32.3 7/28 (25) 167945985 168033177 87192 SPOCK3
4q34.3 8/28 (29) 182485709 182565328 79619
4q34.3 7/28 (25) 181814958 181921046 106088
4q35.2 7/28 (25) 190457567 190574280 116713
4q35.2 8/28 (29) 190712135 190794324 82189
5p12 8/28 (29) 44338589 44428186 89597 FGF10
5p15.2 8/28 (29) 12789319 12879576 90257
5p15.33 9/28 (32) 388661 566921 178260 AHRR, EXOC3, SLC9A3
5p15.33* 7/28 (25) 203859 298137 94278 SDHA
5p15.33 14/28 (50) 557250 688780 131530 SLC9A3, CEP72
5q15 7/28 (25) 57292374 57392374 100000 DNHD2
6p12.2 9/28 (32) 51985699 52087584 101885 PKHD1
6q24.1 8/28 (29) 142584814 142703619 118805 GPR126
7q11.23 9/28 (32) 74705985 74764828 58843
7q22.2 8/28 (29) 105177490 105254527 77037 ATXN7L4
8p23.3 7/28 (25) 1289245 1436212 146967
8p23.3 8/28 (29) 649638 867290 217652 ERICH1, C8orf68
8q22.2 11/28 (39) 99509647 99629754 120107 KCNS2, STK3
8q24.3 9/28 (32) 145298570 145384455 85885
9q22.1 7/28 (25) 90613288 90692980 79692
9q22.32 7/28 (25) 97170096 97284468 114372 PTCH
9q33.3 9/28 (32) 128260025 128347240 87215 C9orf28
10p15.3 9/28 (32) 795549 881206 85657 LARP5
10q11.23 7/28 (25) 52453706 52563182 109476 PRKG1
10q23.1 9/28 (32) 86354131 86459920 105789
10q26.3 8/28 (29) 133716279 133869047 152768 C10orf39, DPYSL4Suk Min Seo, et al.   389
Table 3. Continued
Chromosomal region Frequency (%) Bac_start (bp) Bac_end (bp) Size (bp) Contained genes
10q26.3 9/28 (32) 134604089 134693987 89898 C10orf93
10q26.3 8/28 (29) 134654530 134754530 100000 GPR123
11p15.5 9/28 (32) 982365 1053559 71194 AP2A2, MUC6
11p15.5-p15.4* 9/28 (32) 2812494 2941798 129304
KCNQ1, KCNQ1DN, CDKN1C, 
SLC22A18AS, SLC22A18, PHLDA2, NAP1L4
11p15.5-p15.4 8/28 (29) 2759787 2881783 121996
KCNQ1, KCNQ1DN, CDKN1C, 
SLC22A18AS, SLC22A18
11q12.2 14/28 (50) 60669725 60731709 61984 VPS37C
11q14.1 7/28 (25) 84260432 84364210 103778 DLG2
11q23.1 8/28 (29) 111039892 111136881 96989 SNF1LK2, PPP2R1B
11q23.2 7/28 (25) 114533231 114632257 99026 IGSF4
11q23.3 10/28 (36) 116818967 116903121 84154
11q25 11/28 (39) 133797141 133894154 97013
12p13.33 12/28 (43) 120426 213890 93464 IQSEC3, SLC6A12, SLC6A13
12p13.33 13/28 (46) 183679 257363 73684 SLC6A12, SLC6A13
12p13.33* 9/28 (32) 455498 548935 93437 B4GALNT3, NINJ2
12q22 8/28 (29) 92663057 92746083 83026 CRADD
13q33.3 8/28 (29) 107569780 107652035 82255
14q31.3 8/28 (29) 87706299 87814634 108335 KCNK10
14q32.33 13/28 (46) 105541523 105648959 107436
15q11.2 13/28 (46) 18881005 18958308 77303
15q11.2 10/28 (36) 21607011 21719891 112880
15q25.2 10/28 (36) 80539371 80776796 237425 RPS17
15q26.3 10/28 (36) 100054894 100129431 74537 TARSL2
15q26.3 11/28 (39) 100081440 100155675 74235 TARSL2
15q26.3* 10/28 (36) 99653473 99758817 105344 PCSK6
15q26.3 8/28 (29) 99598506 99716889 118383 CHSY1, SNRPA1, PCSK6
16p11.2 7/28 (25) 32674891 32749246 74355 HERC2P4
16p11.2 8/28 (29) 32022312 32124506 102194
16p11.2 8/28 (29) 33623082 33716863 93781
16p12.1 10/28 (36) 75166320 75276261 109941 ATP9B, NFATC1
16p13.2 10/28 (36) 9930139 10035574 105435 GRIN2A
16q24.1 7/28 (25) 84871012 84981407 110395
17p12 10/28 (36) 14133018 14216943 83925 HS3ST3B1
17q24.3 8/28 (29) 66437827 66557480 119653
17q25.3 8/28 (29) 78432676 78562724 130048 TBCD, B3GNTL1
17q25.3 7/28 (25) 77755881 77849251 93370 SLC16A3, CSNK1D
18q12.3 10/28 (36) 36570635 36662367 91732
18q23* 8/28 (29) 75511317 75607690 96373 CTDP1
18q23 7/28 (25) 75349325 75445847 96522 NFATC1
20p12.2 7/28 (25) 10224066 10314894 90828 SNAP25, RPL23AP6
20q12 9/28 (32) 32614251 32731132 116881 ACACA
20q13.33 8/28 (29) 62273049 62364050 91001 MYT1, PCMTD2
21q11.2 10/28 (36) 13725531 13813182 87651 VN1R8P
21q11.2 7/28 (25) 13890255 13992240 101985 ANKRD21
21q22.3 9/28 (32) 42124137 42238168 114031 PRDM15, C21orf25
22q12.2 7/28 (25) 28407057 28496470 89413 NF2, CABP7390   DNA Copy Number Aberrations in Vasospastic Angina 
Table 3. Continued
Chromosomal region Frequency (%) Bac_start (bp) Bac_end (bp) Size (bp) Contained genes
22q13.33* 9/28 (32) 48930979 49068912 137933
MOV10L1, PANX2, TUBGCP6, HDAC10,
MAPK12, MAPK11, PLXNB2
Loss
2p24.1 7/28 (25) 20200860 20294981 94121 SDC1
4q35.2 12/28 (43) 190963818 191006683 42865
7q22.1* 15/28 (54) 100407386 100480418 73032 MUC12, MUC17
7q36.3 7/28 (25) 157803062 157924916 121854 PTPRN2
10q26.3 9/28 (32) 134755203 134904547 149344 GPR123, KNDC1, UTF1, VENTX
10q26.3 10/28 (36) 134442073 134556094 114021 INPP5A, NKX6-2, C10orf92
15q11.2 11/28 (39) 19958100 20053879 95779 VSIG6
16p13.11 9/28 (32) 16274784 16391850 117066 NOMO3, PKD1P1, PKD1P2
16p13.11 8/28 (29) 14873336 14958740 85404 NOMO1, PKD1P3, NPIP
16p13.3 7/28 (25) 2066833 2157921 91088 TSC2, PKD1, RAB26, TRAF7
17p11.2 9/28 (32) 21826617 21845534 18917
19p13.3 9/28 (32) 292986 371099 78113 MIER2, THEG, KIAA1957
*Verified by reverse transcriptase polymerase chain reaction
Control (XX/XY) 1p35.3 1p12-p11.2
1p22.1
5p15.33
Chr1
Chr11
Chr18
Chr7
Chr15
Chr1-22, X, Y
7q11.1
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
0.6
0.4
0.2
0.0
-0.2
-0.4
0.6
0.4
0.2
0.0
-0.2
-0.4
0.6
0.4
0.2
0.0
-0.2
-0.4
0.6
0.4
0.2
0.0
-0.2
-0.4
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
15q11.1
15q11.2
15q21.3
7q36.3
15q26.3
Fig. 1. Array comparative genomic hybridization (CGH) results. Average log2 ratios (Y axis) of each chromosomal region at 1p, 5p, 7q, 11p, 12p, 
15q, 18q and 22q (X axis) show differences in copy number in spasm patients. Internal control (XX/XY) was used to detect genomic imbal-
ances. Note the high-level aberrations (arrowed spots) on chromosomes.
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Discussion
Several methods including classical cytogenetics, FISH, 
Southern blot analysis, metaphase CGH, and array CGH have 
been used to detect DNA copy number changes.
23) Lately, 
array CGH has been shown to be a powerful tool for detect-
ing genetic aberrations and genetic mapping, and offers high 
resolution, high-throughput, accuracy, and sensitivity for 
genetic analysis.
12-14) It also allows the simultaneous quanti-
tative analysis of all regions of a large genome,
25) and can pro-
Fig. 2. Relative fold differences selected from 8 genes showed that the most frequent gains and losses detected were at 1p, 5p, 7q, 11p, 
12p, 15q, 18q and 22q region. Each sample is depicted (X axis) and the fold difference of N-value was delineated in RT PCR (Y axis). A 
threshold level of 2 (N-value) indicates significant DNA gain (A-G), and 0.5 (N-value) indicates significant DNA loss (H). RT: reverse tran-
scriptase, PCR: polymerase chain reaction, DNA: deoxyribonucleic acid.
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vide quantitative information at the level of chromosomal 
gain or loss.
21) 
Although the confirmation of array-CGH results is usually 
performed by FISH analysis, this technique has several limi-
tations. For example, evaluation of the full extent of genetic 
gains or losses in the genome requires obtaining metaphase 
DNA and interpretion of karyotypes that are often complex 
and require prior knowledge or markers of sites of interest.
2) 
Many recent studies have shown that RT quantitative PCR 
instead of FISH is also a very useful and accurate technique 
for the confirmation of array-CGH results,
17)18)21-24) thus mak-
ing it particularly attractive technique for the identification 
of acquired genetic aberrations in whole blood from patients 
with VA. Therefore, we used RT quantitative PCR for the con-
firmation and quantification of the identified genomic aberra-
tions.
In this study, using array CGH, we have showed than there 
are genetic aberrations and altered genes related to VA. The 
DNA aberrations had a tendency to be located at rather spe-
cific chromosomal regions. Ulike amplification of oncogenes 
or deletions of tumor suppressor genes
21-24) there were no spe-
cific genes amplified or deleted in VA in our study. However, 
many DNA copy number aberrations (91 DNA gains and 12 
DNA losses) were detected. These DNA copy number aber-
rations were novel and different from those previously de-
tected in the Korean population (DNA gains in 6p21.2 and 
DNA loses in 1p36.31, 4q13.1-4q22.13, 16p12.1, 21q22.3, 
and 22q11.22).
31) This showed that many genetic alterations 
might be associated with the pathogenesis of VA. 
Because array CGH shows genetic aberrations at the ge-
nomic DNA level and not at the messenger RNA or protein 
levels, many chromosomal regions which might be related 
to the pathogenesis of VA were found in this study. For ex-
ample, the KCNQ1 gene, one of the genes analyzed by RT 
quantitative PCR,
27) is translated into the potassium voltage-
gated channel subfamily KQT member1, which is probably 
related to cardiac repolarization (www.ihop-net.org/Uni-
Pub/iHOP). Also, the NOTCH2 gene, another one of the 
genes analyzed by RT quantitative PCR, is translated into 
neurogenic locus notch homolog protein 2 precursors; 
notch homolog protein 2 is a receptor for the membrane-
bound ligands involved in regulation of cell-fate determina-
tion (www.ihop-net.org/UniPub/iHOP). However, the func-
tion of the proteins translated by these genes has not been 
completely clarified, so definite pathogenesis of VA cannot 
be established based on our results. Nevertheless, our data may 
become the cornerstone that will establish the function of 
each genetic aberration involved in the pathogenesis of VA.
Conclusion
In summary, using array CGH, we analyzed genome-wide 
chromosomal aberrations and screened chromosomal can-
didate regions related to the pathogenesis of VA. The array-
CGH results were confirmed by RT quantitative PCR. This 
study is the first for searching whole genomic alterations by 
array CGH in patients with VA. Our study may contribute 
to further clarification of important chromosomal regions, 
identification of candidate genes, and understanding of the 
pathogenesis of VA.
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